Bone drug breakthrough: could less be more for cancer patients?

NCT ID NCT04549207

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looks at whether people with breast or prostate cancer that has spread to the bones can safely stop or reduce their bone-strengthening medication after taking it for at least two years. The goal is to see if this change improves their quality of life without increasing bone problems like fractures. About 240 adults are taking part, and they are randomly assigned to either continue their current treatment or reduce/stop it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • Southlake Regional Health Centre

    Newmarket, Ontario, L3Y 2P9, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Thunder Bay Regional Health Sciences Centre

    Thunder Bay, Ontario, P7B 6V4, Canada

  • William Osler Health System

    Brampton, Ontario, L6R 3J7, Canada